Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves selexipag for pulmonary arterial hypertension

chronic-obstructive-pulmonary-disease-copd-woman-with-oxygen-15

Source: Shutterstock.com

Pulmonary arterial hypertension is a rare, progressive lung disease

The US Food and Drug Administrationdrugs (FDA) has approved selexipag to treat adults with pulmonary arterial hypertension (PAH), a chronic and progressive lung disease that causes high pressure in the arteries that connect the heart to the lungs.

The drug, marketed as Uptravi by Actelion Pharmaceuticals, is an oral prostacyclin receptor (IP) agonist. It is indicated to delay disease progression and reduce the risk of hospital admission for PAH. Selexipag, which has been granted orphan drug designation by the FDA, acts by causing vasodilation, reducing elevated arterial pressure.

“Uptravi offers an additional treatment option for patients with pulmonary arterial hypertension,” says Ellis Unger, director of the Office of Drug Evaluation, in the FDA’s Center for Drug Evaluation and Research.

Selexipag’s safety and efficacy were established in a long-term clinical trial of 1,156 participants with PAH, treated for a median of 1.4 years. Patients received selexipag or placebo twice daily and were also allowed to receive background PAH-specific therapy, including an endothelin receptor antagonist (ERA) and phosphodiesterase-5 (PDE-5) inhibitor. At the start of the study, 80% of patients were receiving either an ERA, a PDE-5 inhibitor or a combination of the two.

The trial showed that selexipag reduced hospital admissions related to PAH and reduced the risk of disease progression compared with placebo. Common side effects observed in those treated with selexipag included headache, diarrhoea, jaw pain, nausea, muscle pain, vomiting, pain in an extremity and flushing.

Uptravi will be made available to patients in the United States in early January 2016, says Actelion. The company is also seeking approval in Europe, where the drug is under review by the European Medicines Agency.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200368

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The US drugs safety regulator has approved selexipag to treat adults with pulmonary arterial hypertension. In the image, a woman with respiratory disease is treated with oxygen.

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.